<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05050604</url>
  </required_header>
  <id_info>
    <org_study_id>INFINITE-V (B78_03VCI2004)</org_study_id>
    <nct_id>NCT05050604</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Vascular Cognitive Impairment Patients</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IV Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Mild Cognitive Impairment Patients With Cerebrovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Choline Alfoscerate Re-evaluation Consortium (57 pharmaceutical companies)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, placebo-controlled, Phase IV Trial to&#xD;
      evaluate the efficacy and safety of Choline Alfoscerate compared to placebo in Mild Cognitive&#xD;
      Impairment Patients with Cerebrovascular Disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subject will be randomised in a 1:1 ratio to receive either Choline Alfoscerate or it's&#xD;
      placebo. Investigational Product(IP, Choline Alfoscerate or it's placebo) will be&#xD;
      administered 3 times a day per oral during the treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind (Participant, Investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects whose cognitive function is maintained/improved at 48 weeks compared to baseline</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects reduced by more than or eual 0 points for modified ADAS-Cog score at 24 weeks compared to baseline</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>ADAS-Cog: Alzheimer's Disease Assessment Scale-Cognitive Subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects reduced by more than 2 points of modified ADAS-Cog score at 24 to 48 weeks compared to baseline</measure>
    <time_frame>Baseline, 24 weeks, 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects reduced by more than 4 points of modified ADAS-Cog score at 24 to 48 compared to baseline</measure>
    <time_frame>Baseline, 24 weeks, 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Modified ADAS-Cog score at 24 to 48 weeks compared to baseline</measure>
    <time_frame>Baseline, 24 weeks, 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects increased by more than 0 point of K-MMSE-2 score at 24 and 48 weeks compared to baseline</measure>
    <time_frame>Baseline, 24 weeks, 48 weeks</time_frame>
    <description>K-MMSE-2: Korean version Mini-Mental State Exam-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of K-MMSE-2 score at 24 to 48 weeks compared to baseline</measure>
    <time_frame>Baseline, 24 weeks, 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Modified K-MoCA score at 24 to 48 weeks compared to baseline</measure>
    <time_frame>Baseline, 24 weeks, 48 weeks</time_frame>
    <description>K-MoCA: Korean-Montreal Cognitive Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of CDR-SB score at 48 weeks compared to baseline</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>CDR-SB: Sum of Boxes of Clinical Dementia Rating</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">418</enrollment>
  <condition>Vascular Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Choline Alfoscerate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo of Choline Alfoscerate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Choline Alfoscerate 400mg</intervention_name>
    <description>Choline Alfoscerate 400mg per oral 3 times a day during the entrie treatment period</description>
    <arm_group_label>Choline Alfoscerate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Choline Alfoscerate 400mg</intervention_name>
    <description>Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entrie treatment period</description>
    <arm_group_label>Placebo of Choline Alfoscerate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 50 years&#xD;
&#xD;
          -  Patients with vascular cognitive impairment according to modified Fazekas scale grade&#xD;
             2~3 and/or more than 3 of lacunar infarction in Supratentorial&#xD;
&#xD;
          -  Patients with Clinical Deterioration Rating(CDR) score of 0.5&#xD;
&#xD;
          -  Patients with Korean-Montreal Cognitive Assessment (K-MoCA) score of 23 or less&#xD;
&#xD;
          -  Walk or move using walking aids (i.e., walkers, walking sticks or wheelchairs)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of dementia (including secondary dementia due to Alzheimer's&#xD;
             disease, vascular dementia, infections of the central nervous system (e.g., HIV,&#xD;
             syphilis), Creutzfeld-Jacob disease, Pixie disease, Huntington's disease, Parkinson's&#xD;
             disease, etc.)&#xD;
&#xD;
          -  Medication of dementia within the past 3 months. (e.g., donepezil, galantamine,&#xD;
             rivastigmine, memantine)&#xD;
&#xD;
          -  Medication of brain functional improvement medication within the past 6 weeks. (e.g.,&#xD;
             citicoline, oxiracetam, piracetam, choline alfoscerate, Nicergoline, Nimodipine,&#xD;
             ginko-biloba, acetyl-l carnitine)&#xD;
&#xD;
          -  No studies (no regular school entrance), illiteracy&#xD;
&#xD;
          -  Stroke within the past 3 months&#xD;
&#xD;
          -  Abnormal results from Vitamin B12, Thyroid Stimulated Hormone Test (TSH), HIV-Ab, and&#xD;
             VDRL test contribute to or contribute to cognitive impairment of the subject&#xD;
&#xD;
          -  Serious mental disorders such as severe depression, schizophrenia, alcoholism, drug&#xD;
             dependence, etc.&#xD;
&#xD;
          -  Severe cardiovascular disease such as myocardial infarction, unstable angina or heart&#xD;
             failure within the past 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sun U Kwon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sun U Kwon, MD, PhD</last_name>
    <phone>+82230103440</phone>
    <email>sukwon@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Sun U Kwon</last_name>
      <phone>+82230103440</phone>
      <email>sukwon@amc.seooul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 10, 2021</study_first_submitted>
  <study_first_submitted_qc>September 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vascular Cognitive Impairment</keyword>
  <keyword>Choline Alfoscerate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

